CD28 Down-Regulation on Circulating CD4 T-Cells Is Associated with Poor Prognoses of Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although the etiology of idiopathic pulmonary fibrosis (IPF) remains perplexing, adaptive immune activation is evident among many afflicted patients. Repeated cycles of antigen-induced proliferation cause T-cells to lose surface expression of CD28, and we hypothesized this process might also occur in IPF. METHODOLOGY/PRINCIPAL FINDINGS: Peripheral blood CD4 T-cells from 89 IPF patients were analyzed by flow cytometry and cytokine multiplex assays, and correlated with clinical events. In comparison to autologous CD4(+)CD28(+)cells, the unusual CD4(+)CD28(null) lymphocytes seen in many IPF patients had discordant expressions of activation markers, more frequently produced cytotoxic mediators perforin (2.4+/-0.8% vs. 60.0+/-7.4%, p<0.0001) and granzyme B (4.5+/-2.8% vs.74.9+/-6.5%, p<0.0001), produced greater amounts of many pro-inflammatory cytokines, and less frequently expressed the regulatory T-cell marker FoxP3 (12.9+/-1.1% vs. 3.3+/-0.6% p<0.0001). Infiltration of CD4(+)CD28(null) T-cells in IPF lungs was confirmed by confocal microscopy. Interval changes of CD28 expression among subjects who had replicate studies were correlated with conterminous changes of their forced vital capacities (r(s) = 0.49, p = 0.012). Most importantly, one-year freedom from major adverse clinical events (either death or lung transplantation) was 56+/-6% among 78 IPF patients with CD4(+)CD28(+)/CD4(total)>or=82%, compared to 9+/-9% among those with more extensive CD28 down-regulation (CD4(+)CD28(+)/CD4(total)<82%) (p = 0.0004). The odds ratio for major adverse events among those with the most extensive CD28 down-regulation was 13.0, with 95% confidence intervals 1.6-111.1. CONCLUSIONS/SIGNIFICANCE: Marked down-regulation of CD28 on circulating CD4 T-cells, a result of repeated antigen-driven proliferations, is associated with poor outcomes in IPF patients. The CD4(+)CD28(null) cells of these patients have potentially enhanced pathogenic characteristics, including increased productions of cytotoxic mediators and pro-inflammatory cytokines. These findings show proliferative T-cell responses to antigen(s) resulting in CD28 down-regulation are associated with progression and manifestations of IPF, and suggest assays of circulating CD4 T-cells may identify patients at greatest risk for clinical deterioration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 Flow cytometry methodology (see also references 20, 52). Aliquots of fresh, live peripheral blood mononuclear cells (PBMNC) were stained with anti-CD4-allophycocyanin (APC), anti-CD28-fluorescein isothiocyanate (FITC), and phycoerythrin (PE)-conjugated antibodies against other cell epitopes. A.) Ten thousand (10,000) or more live cells were selected for further study, based their side scatter (SSC) and forward scatter (FSC) characteristics (G1). B.) The brightly staining CD4 cells among these also expressed CD3 (Cy-Chrome) and, thus, are T-cells [52]. C.) These CD4 T-cells were further characterized based on their expression of CD28. The proportions of CD4+CD28+ T-cells among the total CD4+ T-cell population (upper left and upper right quadrants) defines the CD28%. The respective proportions of CD4+CD28+ and CD4+CD28null cells that co-expressed other cell determinants of interest (in this case MHC Class II [DR]) were quantitated. Numbers within the delineated region/quadrants denote the proportions of cells with these respective characteristics.](https://figures.cochat.ai/paper-figures/974f8f991dff4f4c9356985eebda3f1e/cd28-down-regulation-on-circulating-cd4-t-cells-is-associated-with-poor-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“reduced expression of the costimulatory molecule CD28 on circulating T cells was seen to be a predictor of poor outcomes (130).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306 · cited 1×
“(Treg), widely regarded as having important roles in dampening adaptive immune responses against antigens [16], are diminished in both the circulation and broncholavolar lavage returns of IPF patients [17].”
BackgroundIdiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712 · cited 2×
“Nearly all normal CD4 T-lymphocytes express CD28 on their cell surfaces [38], and finding significant proportions of circulating CD4CD28 T-cells is distinctly abnormal [19–34].”
BackgroundIdiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
international consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Tai, X., Cowan, M., Feigenbaum, L., & Singer, A. (2005) · Nature Immunology · doi:10.1038/ni1160 · Cited by 613
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes.
Liuzzo, G., Goronzy, J. J., Yang, H., Kopecky, S. L., Holmes, D. R., Frye, R. L., & Weyand, C. M. (2000) · Circulation · doi:10.1161/01.cir.101.25.2883 · Cited by 552 · cited 10×
“These data demonstrate that the CD4CD28 T-cells of IPF patients exhibit unusual characteristics (Figure 1B and Figure 2) that are very similar to analogous cells isolated from other patient populations with chronic immunologic diseases [19–34].”
BackgroundResultInfluential
Cited by
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Selman, M., & Pardo, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2221pp · Cited by 454
Molecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
“These T cells are activated and antigen experienced [132,135,136], and characterization has shown that both CD4+ and CD8+ cells are present, with the suggestion that CD8+ T cells represent the majority [129-132,137].”
BackgroundHan, M. K., Zhou, Y., Murray, S., Tayob, N., Noth, I., Lama, V. N., Moore, B. B., White, E. S., Flaherty, K. R., Huffnagle, G. B., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70069-4 · Cited by 411
Clonal expansion of CD4+ cytotoxic T lymphocytes in patients with IgG4-related disease
Mattoo, H., Mahajan, V. S., Maehara, T., Deshpande, V., Della-Torre, E., Wallace, Z. S., Kulikova, M., Drijvers, J. M., Daccache, J., Carruthers, M. N., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1330 · Cited by 406
Herazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325
“Given the reported associations of increased number of CD4CD28 T cells in IPF patients with poor outcomes (11), we measured the protein expression by flow cytometry of the T cell costimulatory protein ICOS, the T cell receptor complex protein CD3e, and the tyrosine kinases LCK and ITK among paired autologous CD4CD28 a…”
BackgroundSelf-citationChilosi, M., Carloni, A., Rossi, A., & Poletti, V. (2013) · Translational Research · doi:10.1016/j.trsl.2013.06.004 · Cited by 317
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
“These findings recapitulate an earlier study in which reduced expression of the costimulatory molecule CD28 on circulating T cells was seen to be a predictor of poor outcomes (130).”
ResultThe pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
“produced higher levels of IL-4 and lower levels of IL-10 than CD4þCD28þ lymphocytes [Gilani et al. 2010].”
BackgroundThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
Faner, R., Rojas, M., MacNee, W., & Agustí, A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0282pp · Cited by 268
Fibrosis: ultimate and proximate causes
Thannickal, V. J., Zhou, Y., Gaggar, A., & Duncan, S. R. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74368 · Cited by 242
Self-citationFuture Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
Blackwell, T. S., Tager, A. M., Borok, Z., Moore, B. B., Schwartz, D. A., Anstrom, K. J., Bar-Joseph, Z., Bitterman, P., Blackburn, M. R., Bradford, W., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201306-1141ws · Cited by 236
Self-citationThe Processes and Mechanisms of Cardiac and Pulmonary Fibrosis
Murtha, L. A., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Knight, D. A., & Boyle, A. J. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00777 · Cited by 229
“Whilst both the innate and adaptive immune systems have roles in IPF, the inflammatory response is far less active than in other forms of fibrosis (Feghali-Bostwick et al., 2007; Gilani et al., 2010;Margaritopoulos et al., 2016).”
BackgroundStreitz, M., Miloud, T., Kapinsky, M., Reed, M. R., Magari, R., Geissler, E. K., Hutchinson, J. A., Vogt, K., Schlickeiser, S., Kverneland, A. H., et al. (2013) · Transplantation Research · doi:10.1186/2047-1440-2-17 · Cited by 214
“expression was used as a sign of T cell activation, as previously described [27-32].”
MethodSelman, M., & Pardo, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101393 · Cited by 211
C-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis
Vuga, L. J., Tedrow, J. R., Pandit, K. V., Tan, J., Kass, D. J., Xue, J., Chandra, D., Leader, J. K., Gibson, K. F., Kaminski, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1592oc · Cited by 197
“All subjects with IPF fulfilled American Thoracic Society and European Respiratory Society diagnostic criteria, and had negative conventional autoimmune serologic tests (5, 14, 16, 37).”
BackgroundMethodSelf-citationCytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis
Maehara, T., Kaneko, N., Perugino, C. A., Mattoo, H., Kers, Allard-Chamard, H., Mahajan, V. S., Liu, H., Murphy, S. J. H., Ghebremichael, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131700 · Cited by 192
“In addition to the in-depth investigation of CD4+ CTLs in IgG4-RD, these cells have also been associated with idiopathic pulmonary fibrosis and CD4+ T cells with a cytotoxic phenotype have recently been reported in the context of rheumatoid arthritis (32, 33).”
BackgroundKahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0506oc · Cited by 190
“Intracellular IFN-g and IL-4 production was quantified by flow cytometry (6, 24).”
BackgroundMethodInfluentialSelf-citationMolecular biomarkers in idiopathic pulmonary fibrosis
Ley, B., Brown, K. K., & Collard, H. R. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2014 · Cited by 172
Herazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30349-1 · Cited by 175
Self-citationPlasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J., Vuga, L., Tan, J., Csizmadia, E., Otterbein, L., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 161
“Infiltrates of activated T cells are present in IPF lungs, and the magnitude of these abnormalities is proportionate to disease severity and patient mortality (19, 21, 22).”
BackgroundSelf-citationBlood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
“Circulating cells T-cells (Sema7a /CD28) +/− + Reduce expression of CD28 or increase Sema7a + Treg is associated with a higher mortality [62, 65, 78]”
BackgroundMicrobes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis
Huang, Y., Ma, S.-F., Espindola, M. S., Vij, R., Oldham, J. M., Huffnagle, G. B., Erb-Downward, J. R., Flaherty, K. R., Moore, B. B., White, E. S., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1525oc · Cited by 142
Self-citationReilkoff, R. A., Peng, H., Murray, L. A., Peng, X., Russell, T., Montgomery, R., Feghali-Bostwick, C., Shaw, A., Homer, R. J., Gulati, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201206-1109oc · Cited by 135
Biomarkers in idiopathic pulmonary fibrosis
Drakopanagiotakis, F., Wujak, L., Wygrecka, M., & Markart, P. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.023 · Cited by 132
Blockade of the Programmed Death-1 Pathway Restores Sarcoidosis CD4+ T-Cell Proliferative Capacity
Braun, N. A., Celada, L. J., Herazo‐Maya, J. D., Abraham, S., Shaginurova, G. I., Sevin, C. M., Grutters, J. C., Culver, D. A., Dworski, R., Sheller, J. R., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201401-0188oc · Cited by 143
Self-citationAutoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis
Donahoe, M., Valentine, V. G., Chien, N., Gibson, K. F., Raval, J. S., Saul, M., Xue, J., Zhang, Y., & Duncan, S. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127771 · Cited by 125
“Given many parallels between classical autoimmune syndromes and IPF [3–21,44–46], we hypothesized specific treatments that reduce autoantibodies might also benefit AE-IPF patients.”
BackgroundSelf-citationViruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation
Moore, B. B., & Moore, T. A. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201502-088aw · Cited by 121
Cellular Senescence: Pathogenic Mechanisms in Lung Fibrosis
Parimon, T., Hohmann, M. S., & Yao, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126214 · Cited by 135
“The first study showed that CD4+ CD28null T-cells in BAL were associated with poor prognosis of patients with IPF [182].”
BackgroundAge-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., López-Otín, C., & Pardo, A. (2016) · European Respiratory Journal · doi:10.1183/13993003.00398-2016 · Cited by 122
Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis
Korthagen, N. M., van Moorsel, C. H. M., Barlo, N. P., Ruven, H. J. T., Kruit, A., Heron, M., van den Bosch, J. M. M., & Grutters, J. C. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2010.09.012 · Cited by 119
“Activation markers of circulating immune cells have been associated with IPF progression.(42) How this is a part of IPF pathology and why peripheral YKL-40 production predicts disease progression is still unclear and deserves further research.”
BackgroundPeripheral blood biomarkers in idiopathic pulmonary fibrosis
Vij, R., & Noth, I. (2012) · Translational Research · doi:10.1016/j.trsl.2012.01.012 · Cited by 117
“In a study of 89 subjects with IPF, the proportion of total circulating CD4 T-cells in peripheral blood that expressed CD28 (CD28%) was significantly higher in healthy controls compared to IPF subjects.(82) This finding suggests that CD28 is down-regulated in IPF patients.”
ResultIdiopathic Pulmonary Fibrosis: From Epithelial Injury to Biomarkers - Insights from the Bench Side
Kolb, Borensztajn, K., Crestani, B., & Kolb, M. (2013) · Respiration · doi:10.1159/000357598 · Cited by 113
Biomarkers in idiopathic pulmonary fibrosis
Zhang, Y., & Kaminski, N. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356d03c · Cited by 109
“[42] observed that downregulation of CD28 in circulating CD4 T cells was a marker of poor prognoses in a cohort of 89 IPF patients.”
BackgroundSelf-citationClonally expanded cytotoxic CD4 + T cells and the pathogenesis of IgG4-related disease
Mattoo, H., Stone, J. H., & Pillai, S. S. (2017) · Autoimmunity · doi:10.1080/08916934.2017.1280029 · Cited by 123
Differential role of regulatory T cells in early and late stages of pulmonary fibrosis
Boveda-Ruiz, D., D’Alessandro-Gabazza, C. N., Toda, M., Takagi, T., Naito, M., Matsushima, Y., Matsumoto, T., Kobayashi, T., Gil-Bernabe, P., Chelakkot-Govindalayathil, A.-L., et al. (2013) · Immunobiology · doi:10.1016/j.imbio.2012.05.020 · Cited by 110
Mitochondrial Dysfunction in Pulmonary Fibrosis
Rangarajan, S., Bernard, K. F., & Thannickal, V. J. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201705-370aw · Cited by 116
Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis
Balestro, E., Calabrese, F., Turato, G., Lunardi, F., Bazzan, E., Marulli, G., Biondini, D., Rossi, E., Sanduzzi, A., Rea, F., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0154516 · Cited by 98
CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease
Perugino, C. A., Kaneko, N., Maehara, T., Mattoo, H., Kers, J., Allard‐Chamard, H., Mahajan, V. S., Liu, H., Della‐Torre, E., Murphy, S. J. H., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.022 · Cited by 114
The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis
Murtha, L. A., Morten, M., Schuliga, M. J., Mabotuwana, N. S., Hardy, S. A., Waters, D. W., Burgess, J. K., Ngo, D. T., Sverdlov, A. L., Knight, D. A., et al. (2019) · Aging and disease · doi:10.14336/ad.2018.0601 · Cited by 96
“down-regulation of CD28 (a co-stimulatory molecule for T cells) on CD4 cells also occur in CVD and IPF [42, 43].”
BackgroundGalati, D., De Martino, M., Trotta, A., Rea, G., Bruzzese, D., Cicchitto, G., Stanziola, A. A., Napolitano, M., Sanduzzi, A., & Bocchino, M. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.003 · Cited by 95
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
Samarelli, A. V., Masciale, V., Aramini, B., Coló, G. P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212179 · Cited by 99
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
Perrot, C. Y., Karampitsakos, Τ., & Herazo‐Maya, J. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00302.2023 · Cited by 104
Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis
Li, F. J., Surolia, R., Li, H., Wang, Z., Kulkarni, T., Liu, G., de Andrade, J. A., Kass, D. J., Thannickal, V. J., Duncan, S. R., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700473 · Cited by 85
“T cell–related genes and proteins, such as CD28 and LCK, have been identified as prognostic biomarkers in IPF (13, 16).”
BackgroundMethodSelf-citationRegulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 88
“Activated CD4 T cells (67–69) as well as Tregs (70–73) were found to be upregulated in the peripheral blood of IPF patients and positively correlated with disease severity (67, 68, 70, 71, 73).”
BackgroundIdiopathic Pulmonary Fibrosis—an Epidemiological and Pathological Review
Borchers, A. T., Chang, C. C., Keen, C. L., & Gershwin, M. E. (2010) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8211-5 · Cited by 88
Rieder, F., de Bruyn, J. R., Pham, B. T., Katsanos, K. H., Annese, V., Higgins, P., Magro, F., & Dotan, I. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.03.009 · Cited by 82
T cells in idiopathic pulmonary fibrosis: crucial but controversial
Deng, L., Huang, T., & Zhang, L. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01344-x · Cited by 74
Jee, A. S., Sahhar, J., Youssef, P. P., Bleasel, J. F., Adelstein, S., Nguyen, M., & Corte, T. J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.014 · Cited by 79
Fernandez, I. E., Greiffo, F. R., Frankenberger, M., Bandres, J., Heinzelmann, K., Neurohr, C., Hatz, R., Hartl, D., Behr, J., & Eickelberg, O. (2016) · European Respiratory Journal · doi:10.1183/13993003.01826-2015 · Cited by 75
Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night
Schiza, S. E., Mermigkis, C. M., Margaritopoulos, G. A., Daniil, Z. D., Harari, S. A., Poletti, V. E., Renzoni, E. A., Torre, O., Visca, D., Bouloukaki, I., et al. (2015) · European Respiratory Review · doi:10.1183/16000617.00009114 · Cited by 76
Cartilage Oligomeric Matrix Protein in Idiopathic Pulmonary Fibrosis
Vuga, L. J., Milosevic, J., Pandit, K., Ben-Yehudah, A., Chu, Y., Richards, T., Sciurba, J., Myerburg, M., Zhang, Y., Parwani, A. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083120 · Cited by 74
Self-citationA functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
Huang, Y., Ma, S., Vij, R., Oldham, J. M., Herazo‐Maya, J. D., Broderick, S. M., Strek, M. E., White, S. R., Hogarth, D. K., Sandbo, N. K., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0142-8 · Cited by 77
“Down-regulation of CD28 on circulating CD4 T-cells has been associated with poor outcomes in IPF patients [29].”
BackgroundResultSelf-citationInto the matrix: targeting fibroblasts in pulmonary fibrosis
Sivakumar, P., Ntolios, P., Jenkins, G., & Laurent, G. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356800f · Cited by 67
“[33] recently reported that peripheral T-lymphocytes from IPF patients had diminished CD28 expression, expressed aberrant markers of activation and produced large amounts of proinflammatory cytokines compared with autologous CD4þ T cells, changes that were associated with poor prognosis.”
BackgroundIdiopathic pulmonary fibrosis and a role for autoimmunity
Hoyne, G. F., Elliott, H., Mutsaers, S. E., & Prêle, C. M. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.22 · Cited by 78
CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions
Re, S. L., Lison, D., & Huaux, F. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.0512261 · Cited by 68
“Indeed, CD28 or CCR4 CD4 T lymphocytes are specifically recruited and may identify patients at high risk for clinical deterioration [90].”
BackgroundAgeing mechanisms that contribute to tissue remodeling in lung disease
Schuliga, M. J., Read, J. M., & Knight, D. A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101405 · Cited by 65
Moore, B. B., Fry, C., Zhou, Y., Murray, S., Han, M. K., Martinez, F. J., Flaherty, K. R., & The COMET Investigators (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00056 · Cited by 60
“baseline lung function than in our cohort (7).”
Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF
Ashley, S. L., Xia, M., Murray, S., O’Dwyer, D. N., Grant, E. P., White, E. S., Flaherty, K. R., Martínez, F. J., & Moore, B. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159878 · Cited by 70
“Conversely, in IPF peripheral blood mononuclear cells (PBMCs), decreased expressions of ICOS, CD28 and lymphocyte-specific protein tyrosine kinase (LCK) are seen in more severe disease [15].”
BackgroundInfluentialCharacterization of CD28null T cells in idiopathic pulmonary fibrosis
Habiel, D. M., Espíndola, M. S., Kitson, C., Azzara, A. V., Coelho, A. L., Stripp, B. R., & Hogaboam, C. M. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0082-8 · Cited by 64
Hambly, N., Shimbori, C., & Kolb, M. (2015) · Respirology · doi:10.1111/resp.12569 · Cited by 55
The HLA Class II Allele DRB1*1501 Is Over-Represented in Patients with Idiopathic Pulmonary Fibrosis
Xue, J., Gochuico, B. R., Alawad, A. S., Feghali-Bostwick, C. A., Noth, I., Nathan, S. D., Rosen, G. D., Rosas, I. O., Dacic, S., Ocak, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014715 · Cited by 58
“, are also present in the circulation (and lungs) of IPF patients singularly destined for poor outcomes”
BackgroundSelf-citationIdiopathic Pulmonary Fibrosis: Diagnosis and Prognostic Evaluation
Poletti, V. E., Ravaglia, C., Buccioli, M., Tantalocco, P., Piciucchi, S., Dubini, A., Carloni, A., Chilosi, M., & Tomassetti, S. (2013) · Respiration · doi:10.1159/000353580 · Cited by 56
Fibrosis: Lessons from OMICS analyses of the human lung
Yu, G., Ibarra, G. H., & Kaminski, N. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.014 · Cited by 52
Self-citationThe aging lung: microenvironment, mechanisms, and diseases
Wang, Y., Huang, X., Luo, G., Xu, Y., Deng, X., Lin, Y., Wang, Z., Zhou, S., Wang, S., Chen, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383503 · Cited by 66
Epigenomics of Idiopathic Pulmonary Fibrosis
Yang, I. V. (2012) · Epigenomics · doi:10.2217/epi.12.10 · Cited by 54
“More recent studies have demonstrated global Treg impairment in IPF that strongly correlates with disease severity [61] and an association of CD28 downregulation on circulating CD4 T cells with a poor prognosis in patients with IPF [62].”
BackgroundKulkarni, T., Yuan, K., Tran-Nguyen, T. K., Kim, Y.-I., de Andrade, J. A., Luckhardt, T., Valentine, V. G., Kass, D. J., & Duncan, S. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0221905 · Cited by 52
“BMI decre- ments were significantly associated with increased proportions of circulating enddifferentiated (CD28null) CD4 T-cells (CD28%), a validated marker of repetitive T-cell activa- tion and IPF prognoses.”
BackgroundMethodSelf-citationXie, Y., Shi, S., Lv, W., Wang, X., Yue, L., Deng, C., Wang, D., Han, J., Ye, T., & Lin, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c06598 · Cited by 54
Serum biomarkers in idiopathic pulmonary fibrosis
van den Blink, B., Wijsenbeek, M. S., & Hoogsteden, H. C. (2010) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2010.08.001 · Cited by 48
Cytotoxic CD4+ tissue-resident memory T cells are associated with asthma severity
de la Mata, S. H., Ramírez-Suástegui, C., Mistry, H. M., Castañeda-Castro, F. E., Kyyaly, A., Simon, H. A., Liang, S. Y., Lau, L. C. K., Barber, C., Mondal, M., et al. (2023) · Med · doi:10.1016/j.medj.2023.09.003 · Cited by 57
Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings
Renzoni, E. A., Veeraraghavan, S., & Sestini, P. (2014) · F1000Prime Reports · doi:10.12703/p6-69 · Cited by 60
“Indeed, Gilani and colleagues found that increased proportions of circulating CD28CD4 T cells are associated with poor outcomes in patients with IPF [80].”
BackgroundAdegunsoye, A., Hrusch, C. L., Bonham, C. A., Jaffrey, M. R., Blaine, K. M., Sullivan, M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00516 · Cited by 48
“Unlike the lungs, circulating CD4+ T cells are present in similar numbers in IPF patients and controls, or are even decreased in IPF patients (27, 30).”
BackgroundIdiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations
Nakamura, Y., & Suda, T. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s39897 · Cited by 49
Systemic sclerosis-associated fibrosis: an accelerated aging phenotype?
Luckhardt, T., & Thannickal, V. J. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000219 · Cited by 41
Role of Mesenchymal Stem Cells and Extracellular Vesicles in Idiopathic Pulmonary Fibrosis
Kletukhina, S. K., Mutallapova, G., Андреевна, Т. А., & Gomzikova, M. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911212 · Cited by 40
“In addition, decreased expression of CD28 on circulating T cells is associated with adverse outcomes in patients with IPF [167].”
BackgroundExisting and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis
Inchingolo, R., Varone, F., Sgalla, G., & Richeldi, L. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1553620 · Cited by 37
Pennathur, S., Vivekanandan-Giri, A., Locy, M. L., Kulkarni, T., Zhi, D., Zeng, L., Byun, J., de Andrade, J. A., & Thannickal, V. J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0992oc · Cited by 36
Mattoo, H., & Pillai, S. S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03874-y · Cited by 40
Advancing Respiratory Research
Kiley, J. P. (2011) · CHEST Journal · doi:10.1378/chest.11-0774 · Cited by 37
Selman, M., Martinez, F. J., & Pardo, A. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201806-1166pp · Cited by 35
The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases
Doyle, T. J., Pinto-Plata, V., Morse, D., Celli, B. R., & Rosas, I. O. (2012) · CHEST Journal · doi:10.1378/chest.12-1540 · Cited by 36
The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang, A., Liu, N., Wang, J., Zheng, X., Ren, M., Zhang, W., & Yao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022228 · Cited by 34
Ashley, S. L., Jegal, Y., Moore, T. A., van Dyk, L. F., Laouar, Y., & Moore, B. B. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2013 · Cited by 39
“Mounting clinical evidence suggests that patients with IPF have T cells with low expression of CD28 (10, 13).”
BackgroundIs personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Amnion Epithelial Cells Promote Lung Repair via Lipoxin A4
Tan, J. L., Tan, Y. Z., Muljadi, R. C. M., Chan, S. T., Lau, S. N., Mockler, J. C., Wallace, E. M., & Lim, R. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0077 · Cited by 32
Vera, E. J., Chew, Y. V., Nicholson, L., Burns, H., Anderson, P., Chen, H.-T., Williams, L. J., Keung, K. L., Zanjani, N. T., Dervish, S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217163 · Cited by 30
Ghosh, A., Hobbs, B. D., Yun, J. H., Saferali, A., Moll, M. R., Xu, Z., Chase, R., Morrow, J. D., Ziniti, J. P., Sciurba, F. C., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02013-w · Cited by 30
“Similarly, downregulation of CD28 on CD4 T cells has been shown to be associated with a dysregulated, increased immune response associated with progression of IPF [41].”
BackgroundZhu, H., Zhu, C., Mi, W., Chen, T., Zhao, H., Zuo, X., Luo, H., & Li, Q. (2018) · International Journal of Rheumatology · doi:10.1155/2018/7342472 · Cited by 29
Emerging drugs for idiopathic pulmonary fibrosis
Selman, M., Pardo, A., Richeldi, L., & Cerri, S. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.565049 · Cited by 29
“Thus for instance, marked downregulation of CD28 on circulating CD4 T cells has been found in some patients with IPF and appears to identify patients at greatest risk for clinical deterioration [26].”
BackgroundInterrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases
Lai, Y., Wei, X., Ye, T., Hang, L.-L., Mou, L., & Su, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747335 · Cited by 28
Personalized Medicine: Applying ‘omics’ to Lung Fibrosis
Herazo‐Maya, J. D., & Kaminski, N. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.38 · Cited by 25
Self-citationRecent advances in pulmonary fibrosis: implications for scleroderma
Homer, R., & Herzog, E. L. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833ddcc9 · Cited by 24
Regulatory T Cells in Idiopathic Pulmonary Fibrosis
Moore, M. W., & Herzog, E. L. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.002 · Cited by 26
Maldonado, M., Buendía-Roldán, I., Vicens‐Zygmunt, V., Planas‐Cerezales, L., Molina‐Molina, M., Selman, M., & Pardo, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203779 · Cited by 24
Biondini, D., Balestro, E., Lacedonia, D., Cerri, S., Milaneschi, R., Luppi, F., Cocconcelli, E., Bazzan, E., Clini, E. M., Barbaro, M. P. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24303-4 · Cited by 25
Towards a better diagnosis of idiopathic pulmonary fibrosis
Valeyre, D. (2011) · European Respiratory Review · doi:10.1183/09059180.00001611 · Cited by 24
Ilyas, S. Z., Tabassum, R., Hamed, H., Rehman, S. U., & Qadri, I. (2017) · Viral Immunology · doi:10.1089/vim.2017.0009 · Cited by 22
“In addition to this, IPF + HCV patients have higher mean age suggestive of the immunosenescence, particularly in case of viral infections (25,59), along with different spatial or temporal morphology of the lung indicative of reminiscent infection (27,58).”
Metadata
- Authors
- Gilani, S. R., Vuga, L. J., Lindell, K. O., Gibson, K. F., Xue, J., Kaminski, N., Valentine, V. G., Lindsay, E. K., George, M. P., Steele, C., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- The University of Texas Medical Branch at Galveston (US)
- University of Alabama at Birmingham (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-01-29
- Volume
- 5
- Issue
- 1
- Pages
- e8959
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2813297
- OpenAlex
- W1976574577
- Cited by
- 203
- References
- 54
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 15 · 2023: 14 · 2022: 11 · 2021: 12 · 2020: 9 · 2019: 9 · 2018: 18 · 2017: 14 · 2016: 11 · 2015: 14 · 2014: 13 · 2013: 18 · 2012: 18
- FWCI
- 13.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- University of Pittsburgh
- National Institutes of Health (5r01hl073241-04, 5p50hl084932-05)
- National Heart, Lung, and Blood Institute (R01 HL073241, P50-HL-084932, 1P50 HL084932, 1R01HL073241, T32HL007563)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- idiopathic pulmonary fibrosis, CD4+ T cells, T cell exhaustion, prognostic factors, perforin, granzyme B, Foxp3+ regulatory T cells, inflammatory cytokines, lung transplantation, forced vital capacity, adaptive immune activation, lung infiltration, major adverse clinical events, T cell activation markers
- MeSH terms
- Adult, Humans, Male, Prognosis, Pulmonary Fibrosis, CD4-Positive T-Lymphocytes, Down-Regulation, CD28 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.